These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21687916)

  • 1. Anticoagulants. Old and new.
    Levi M; Eerenberg ES; Kampuisen PW
    Hamostaseologie; 2011 Nov; 31(4):229-35. PubMed ID: 21687916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bleeding with anticoagulant treatments.
    Palareti G
    Hamostaseologie; 2011 Nov; 31(4):237-42. PubMed ID: 21709932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy.
    Majeed A; Eelde A; Agren A; Schulman S; Holmström M
    Thromb Res; 2012 Feb; 129(2):146-51. PubMed ID: 21807399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management.
    Levi MM; Eerenberg E; Löwenberg E; Kamphuisen PW
    Neth J Med; 2010 Feb; 68(2):68-76. PubMed ID: 20167958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology and management of bleeding in patients using vitamin K antagonists.
    Levi M
    J Thromb Haemost; 2009 Jul; 7 Suppl 1():103-6. PubMed ID: 19630779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergency reversal of anticoagulation: the real use of prothrombin complex concentrates: a prospective multicenter two year French study from 2006 to 2008.
    Desmettre T; Dubart AE; Capellier G; Fanara B; Puyraveau M; Kepka S; Coquart J; Sheppard F; Tazarourte K
    Thromb Res; 2012 Sep; 130(3):e178-83. PubMed ID: 22726885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bleeding risks associated with vitamin K antagonists.
    Linkins LA
    Blood Rev; 2013 May; 27(3):111-8. PubMed ID: 23473948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of bleeding in patients using antithrombotic agents: prediction, prevention, protection and problem-oriented intervention.
    Scharf RE
    Hamostaseologie; 2009 Nov; 29(4):388-98. PubMed ID: 19882082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent thromboembolism in cancer patients: incidence and risk factors.
    Prandoni P; Piccioli A; Pagnan A
    Semin Thromb Hemost; 2003 Dec; 29 Suppl 1():3-8. PubMed ID: 14730471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current concepts for the prevention of venous thromboembolism.
    Bramlage P; Pittrow D; Kirch W
    Eur J Clin Invest; 2005 Mar; 35 Suppl 1():4-11. PubMed ID: 15701142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Perioperative control of vitamin K antagonists in elective surgery].
    Revigliono JI; Cornavaca T; Becerra F; Albertini R; Contreras AE; Tabares A
    Medicina (B Aires); 2014; 74(5):385-90. PubMed ID: 25347900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended prophylaxis of venous thromboembolism with idraparinux.
    ; Buller HR; Cohen AT; Davidson B; Decousus H; Gallus AS; Gent M; Pillion G; Piovella F; Prins MH; Raskob GE
    N Engl J Med; 2007 Sep; 357(11):1105-12. PubMed ID: 17855671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bleeding risk assessment and management in atrial fibrillation patients. Key messages for clinical practice from the European Heart Rhythm Association position statement.
    Guo Y; Lip GY; Apostolakis S
    Pol Arch Med Wewn; 2012; 122(5):235-42. PubMed ID: 22660688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Optimum duration of anticoagulant treatment after an episode of venous thromboembolism].
    Couturaud F; Kearon C
    Rev Pneumol Clin; 2008 Dec; 64(6):305-15. PubMed ID: 19084210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation for venous thromboembolism: what if they bleed?
    Palareti G
    Hamostaseologie; 2012; 32(1):40-4. PubMed ID: 22009202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism.
    Torn M; van der Meer FJ; Rosendaal FR
    Arch Intern Med; 2004 Mar; 164(6):668-73. PubMed ID: 15037497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
    Cairns JA; Connolly S; McMurtry S; Stephenson M; Talajic M;
    Can J Cardiol; 2011; 27(1):74-90. PubMed ID: 21329865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding rates in patients older than 90 years of age on vitamin K antagonist therapy for nonvalvular atrial fibrillation.
    Tincani E; Baldini P; Crowther MA; Zanasi A; Ferrari P; Cenci AM; Rioli G
    Blood Coagul Fibrinolysis; 2009 Jan; 20(1):47-51. PubMed ID: 20523164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The practical management of intracerebral hemorrhage associated with oral anticoagulant therapy.
    Masotti L; Di Napoli M; Godoy DA; Rafanelli D; Liumbruno G; Koumpouros N; Landini G; Pampana A; Cappelli R; Poli D; Prisco D
    Int J Stroke; 2011 Jun; 6(3):228-40. PubMed ID: 21557810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of excessive anticoagulation or bleeding.
    Makris M
    Semin Vasc Med; 2003 Aug; 3(3):279-84. PubMed ID: 15199461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.